NVSEF — NOVARTIS AG
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1114448 ·
Last close
$158.52
Market Cap
$301.30B
52W High
$160.00
52W Low
$139.32
ADV30
7,313
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 14,951,000,000 | 11,241,000,000 | 4,750,000,000 | 3,264,000,000 | 122,033,000,000 | 7,616,000,000 | 80,087,000,000 |
| Mar 2026 | 13,524,000,000 | 10,065,000,000 | 4,235,000,000 | 3,156,000,000 | 118,532,000,000 | 6,877,000,000 | 79,605,000,000 |
| Dec 2025 | 13,860,000,000 | 10,249,000,000 | 3,616,000,000 | 2,409,000,000 | 110,949,000,000 | 11,435,000,000 | 64,400,000,000 |
| Sep 2025 | 14,358,000,000 | 10,819,000,000 | 4,501,000,000 | 3,928,000,000 | 107,289,000,000 | 9,556,000,000 | 62,537,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,175,000,000
Investing CF
$-16,943,000,000
Financing CF
$-2,740,000,000
CapEx
$-3,213,000,000
Dividends Paid
$-14,015,000,000
Buybacks
$-8,371,000,000
EPS Diluted TTM
$6.78
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$37,252,000,000
Inventory
$6,286,000,000
Receivables
$9,602,000,000
ST Investments
$100,000,000
EBIT TTM
$17,001,000,000
Pretax Income TTM
$15,784,000,000
Interest Exp TTM
$1,217,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,692,998,144
EBITDA
$23,097,999,360
Free Cash Flow
$11,900,250,112
Enterprise Value
$343,101,308,928
Total Cash
$7,617,999,872
Total Debt
$49,014,001,664
Shares Out
1,900,714,840
Trailing EPS
$6.63
Book Value
$21.86
ROE
30.3%
ROA
10.2%
Div Yield
2.99%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 56,674,000,000 | 17,644,000,000 | 13,984,000,000 | 111,000,000,000 | 64,400,000,000 | — | 19,144,000,000 |
| Dec 2024 | 51,722,000,000 | 14,544,000,000 | 11,941,000,000 | 102,246,000,000 | 58,120,000,000 | — | 17,619,000,000 |
| Dec 2023 | 46,660,000,000 | 9,769,000,000 | 14,850,000,000 | 99,945,000,000 | 53,195,000,000 | — | 14,458,000,000 |
| Dec 2022 | 43,461,000,000 | 7,946,000,000 | 6,955,000,000 | 117,453,000,000 | 58,030,000,000 | — | 14,236,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVS | NOVARTIS AG | $296.80B | $156.15 | — |
| MRK | Merck & Co., Inc. | $321.57B | $130.20 | — |
| AZN | ASTRAZENECA PLC | $263.09B | $169.64 | — |
| ABBV | AbbVie Inc. | $443.36B | $250.94 | — |
| ABT | ABBOTT LABORATORIES | $184.11B | $105.70 | — |
News headlines (Yahoo Finance, 1h cache)
Novartis (SWX:NOVN) Wins FDA Approval For Pluvicto In Earlier Prostate Cancer
2026-08-02 10:06 · Yahoo
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
2026-07-31 20:25 · Yahoo
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
2026-07-31 15:25 · Yahoo
Alnylam Pharmaceuticals Inc (ALNY) (Q2 2026) Earnings Call Highlights: Amvuttra Surpasses $1 ...
2026-07-30 21:04 · Yahoo
How Telix landed a $2.1 billion radiopharma deal with Regeneron
2026-07-30 09:12 · Yahoo
3 Dividend Stocks to Buy for a Lifetime of Passive Income
2026-07-29 17:20 · Yahoo
Why Biogen Stock Is Resisting a Market Downturn After Earnings
2026-07-29 16:21 · Yahoo
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
2026-07-28 16:40 · Yahoo
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
2026-07-27 16:36 · Yahoo
Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
2026-07-27 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.